ALEMBIC LTD. Q4 FY26 Results

Summary

Alembic Limited achieved consolidated revenue from operations of ₹23,999 lakhs for the financial year ended March 31, 2026, representing an 8.16% year-on-year growth. The company's consolidated Net Profit after tax and Share of Associate's Profit/(Loss) for FY26 also increased by 2.16% to ₹31,738 lakhs. However, for the fourth quarter, consolidated revenue from operations saw a marginal decline of 0.38% year-on-year to ₹6,004 lakhs, while consolidated Profit Before Tax for the full year decreased by 4.33%. A notable highlight includes the strong performance of the Active Pharmaceutical Ingredients (API) business segment, which registered a 44.6% increase in revenue for the full year. Furthermore, the Board has recommended a dividend of ₹2.40 per equity share for FY26.

Key Highlights

1. 1

   Alembic Limited reported consolidated revenue from operations of ₹23,999 lakhs for the financial year ended March 31, 2026, an 8.16% increase compared to ₹22,189 lakhs in FY25.

2. 2

   Consolidated Net Profit after tax and Share of Associate's Profit/(Loss) for FY26 grew by 2.16% to ₹31,738 lakhs, up from ₹31,068 lakhs in the previous financial year.

3. 3

   For the quarter ended March 31, 2026, consolidated revenue from operations stood at ₹6,004 lakhs, a marginal decrease of 0.38% year-on-year.

4. 4

   Consolidated Profit Before Tax (PBT) for FY26 decreased by 4.33% to ₹14,876 lakhs, compared to ₹15,550 lakhs in FY25.

5. 5

   The Active Pharmaceutical Ingredients (API) business segment recorded robust full-year revenue growth of 44.6%, reaching ₹4,659 lakhs in FY26 from ₹3,221 lakhs in FY25.

6. 6

   The company's Board of Directors has recommended a dividend of ₹2.40 per Equity Share (120%) for the financial year ended March 31, 2026.

7. 7

   Consolidated Earnings per Share (Basic & Diluted) for FY26 slightly improved by 2.15% to ₹12.36 from ₹12.10 in FY25.